South Korea’s SK Plasma will build a blood products plant in Indonesia.
Industry sources on Tuesday said the company recently received approval from the Indonesian Ministry of Health to build the facility.
Blood products are medicines for treating diseases caused by lack of specific components in blood.
The company will also set up a joint venture with Indonesian pharmaceutical partner PT Infion to build the factory.
To be built near Jakarta, the plant will possess annual processing capacity of about a million liters of human plasma.
The plant will mainly churn out Albumin and Liv-Gamma. Albumin is used for burns and hemorrhagic shock and Liv-Gamma for regulating abnormal immune responses in autoimmune diseases.
SK Plasma forecasts sales of around 300 billion won ($227.8 million) from the plant.
The blood product company was launched in 2015 after being spun off from SK Chemicals.
Write to Jae-Young Han at
jyhan@hankyung.com
